Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Korea’s OTC Drug Sales In Supermarkets Stalled At National Assembly

This article was originally published in PharmAsia News

Executive Summary

Ruling party and opposition lawmakers clashed this week during ratification of the Korea-U.S. FTA in the National Assembly, but both sides are currently united in refusing the establishment of a new law to expand sales channels for OTC drugs.

You may also be interested in...

Korea Allows Sales Of OTC Products In Supermarkets July 21, But Distribution Remains A Challenge

SEOUL - South Koreans are expected to be able to purchase 48 new over-the-counter products at supermarkets and conveniences stores, previously only available at pharmacies, beginning July 21, but consumers found that companies need more time to allow for the expanded distribution and manufacturing

Korea's Pharmacists, Doctors Clash Over Prescription Drug Sales; Ministry Calls For Expanded Painkiller Distribution

SEOUL - What started as a simple task of widening public access to some over-the-counter drugs has now evolved into a turf war between South Korea's pharmacist and doctor associations, and the Ministry of Health And Welfare is now calling for a new round of OTC distribution revisions before the first round has finished

Early-Stage Idiopathic Pulmonary Fibrosis (IPF) Candidates Race to Phase III

Multiple IPF drugs are being rushed into Phase III based on early-stage signals of efficacy and safety presented at the ATS meeting. Scrip spoke with the University of Pittsburgh's Kevin Gibson about the candidates, trial design, combination therapy and limitations of current therapy.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts